PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Group Art Unit 1806 :

In re application of

HITOSHI NAGAOKA : INHIBITOR OF HEPATITIS B

AND HIV ACTIVITY

Serial No. 08/257,355

Filed June 9, 1994 :

Pittsburgh, Pennsylvania

September 9, 1994

INFORMATION DISCLOSURE STATEMENT

Hon. Commissioner of Patents and Trademarks Washington, D.C. 20231

Sir:

Pursuant to 37 C.F.R. §§1.97-1.98, Applicant hereby submits this Information Disclosure Statement which includes a completed Form PTO-1449 and one (1) copy of each prior art reference listed thereon. In addition, English abstracts of the Japanese Patent Nos. 60-23826/1985; 4-35149/1992; and 4-6171/1992 are enclosed.

The references identified in Form PTO-1449 are referred to on pages 2, 3 and 10 of the specification and are relevant for the reasons stated therein. Applicant cited pp. 317-331 of the "Antiviral Research" reference in the specification. However, Applicant is enclosing only pages 317, 321 and 322 of this

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner of Patents and Trademarks, Washington, D.C. 20231 on September 9, 1994.

Nome of Registered Representative)

(Nome of Registered Representative)

Signature Date



reference in this Information Disclosure Statement. Page 317 is the first page of the reference and pages 321 and 322 contain the only passages of relevance.

Pursuant to 37 C.F.R. §1.97(b)(1), no fee is believed to be due for the submission of this Information Disclosure Statement as it is being submitted within three months of the filing date of the patent application. Nevertheless, the Commissioner of Patents and Trademarks is hereby authorized to charge any additional fees which may be required to Deposit Account No. 23-650 or refund any overpayment in the form of a check. One original and two copies of this Information Disclosure Statement are enclosed.

Examination and allowance of claims 1-4 and 8-10 are respectfully submitted.

Respectfully submitted,

WEBB ZIESENHEIM BRUENING LOGSDON ORKIN & HANSON, P.C.

RA_

Barbara E. Johnson

Registration No. 31,198 Attorney for Applicant 700 Koppers Building

436 Seventh Avenue

Pittsburgh, PA 15219-1818 Telephone: (412) 471-8815

Facsimile: (412) 471-4094

Sheet_1_o	f.	2
-----------	----	---

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE											<u> </u>	ATTY. DOCKET NO. SERIAL NO. 1217/940247 08/257,35								
INFORMATION DISCLOSURE STATEMENT BY APPLICANT												APPLICANT / Hitoshi NAGAOKA								
	(Use several sheets if necessary)												FILING DATE June 9, 1994				GROUP Art Unit 1806			
								_		U	.S. P.	ATENT	DOCU	MENTS						
EXAMINER INITIAL			DO	CUP	ENT	· NU	IMBE	R	DA	DATE			NAME			SUBCLASS	FILING DATE IF APPROPRIATE			
	AA																			
	AB			L				L												
	AC			L		L	L	L							<u> </u>					
	AD	\perp	L	L	L	\perp	L	\perp							<u> </u>					
	AE	_	_	_	1	L	\perp	$oldsymbol{\perp}$	ļ		<u> </u>				<u> </u>			-		
	AF	\perp			_	L	L	L			<u> </u>									
	AG	<u> </u>	_	_	<u> </u>	↓_	<u> </u>	_	<u> </u>		ļ			,	ļ					
	AH	 	_	L	<u> </u>	 	_	_	<u> </u>		ļ				 	 	 			
	AI	<u> </u>	<u> </u>	1	↓_	L	↓_	L			ļ				ļ	ļ				
	AJ	<u> </u>	_	_	_	<u> </u>	↓_	_			ļ			 	ļ					
	AK			L	\perp	_	1_		L		<u></u>				1					
	<u>,</u>									FOR	REIGN	PATE	NT DO	CUMENT	S 	,				
																	TRANSL	_ATION		
		_	DOCUMENT NUMBER DATE								ļ	COU	NTRY		CLASS	SUBCLASS	YES	NO ·		
·	AL	6	0	2	3	8	2	6	06/1	0/85	Japan			<u> </u>	A23 L 2	38	×			
	AM	<u> </u>	L	4	6	1	7	1	02/0	5/92	Japan				A61 K35	84	×			
	AN	_	4	3	5	1	4	9	06/1	0/92	Japan				A23 L 2	38	×	<u> </u>		
	A0	_	L	L	_	_	<u> </u>	_										<u> </u>		
	AP	L_	_	_	L	<u> </u>	L	<u> </u>			<u> </u>			 -	<u> </u>			1		
		,	OTH	IER	DC	CUI	MEN	TS	(Incl	uding	Autho	r, Tit	le, Dat	e, Pert	inent Pa	ges, Etc.	· · · · · · · · · · · · · · · · · · ·			
	AQ	-	Te	tsu	o T	agu	chi	et	al., 1	BIOTHE	RAPY, Vo	ol. 2, N	lo. 3 (19	988) pp.	509-521	··· ··· ··· ···		 		
	45		На	arumi Suzuki et al., Inhibition of the Infectivity and Cytopathic Effect of Human,																
	AR		В	осн	EMI	CAL	AN	D B	OPHYS	CAL R	ESEARCH	COMMUNI	CATIONS	, Vol. 16	0, No. 1	(1989) pp.	367-373			
	45		На	rum	i S	uzu	ki	et a	al., S	tructu	ral Chai	racteriz	ation o	f the Imm	nunoactive	and Antivi	ra1,			
	AS	Agric. Biol. Chem., Vol. 54, No. 2 (1990) pp. 479-487																		
EXAMIN	MINER DAT											DNSIDERED								

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE										ATTY. DOC 1217/9402		SERIAL NO. 08/257,355			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)										APPLICANT Hitoshi N		GROUP Art Unit 1806			
										FILING DA June 9, 1	TE 994				
		-	- *					U	.S. PA	TENT DOCUMEN	ITS				
EXAMINER INITIAL		DC	DOCUMENT NUMBER DA							NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
	AA											·			
	AB														
	AC														
	AD														
	AE]						
	AF														
	AG														
	AH												,		
	AI		\Box		П										
	AJ														
	AK	7												· · · · · · · · · · · · · · · · · · ·	
	·		h		L			FOR	EIGN	PATENT DOCUM	ENTS	•			
				_		-						TRANSLATION			
		DO	DOCUMENT NUMBER DA					DATE		COUNTRY	CLASS	SUBCLASS	YES	NO ·	
	AL	-						·				·		 -	
	AM		\sqcup						ļ	· · · · · · · · · · · · · · · · · · ·		<u> </u>			
· · · · · · · · · · · · · · · · · · ·	AN		1-1					: 				ļ		ļ	
	AO		\sqcup	_										ļ	
	AP											<u> </u>			
										, Title, Date,					
	AQ	_ Y	Yoshio Inouye et al., In Vitro Antiviral Activity of Polyoxomolybdates,												
		A	ntiv	ira	al R	ese	earc	h, Vol. 20	(1993) p	317, 321-322					
	AR -	-													
	AS -	+													
EXAMINE	IR			-					DATE CO	CONSIDERED					

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.